Recent advances in clinical research of humanized monoclonal antibodies against respiratory syncytial virus infection in infants

VernacularTitle:预防婴儿呼吸道合胞病毒感染的人源化单克隆抗体临床研究最新进展
Author: Zhengde XIE ¹ ; Yuejie ZHENG ; Gen LU ; Fengxia XUE ; Kunling SHEN
Author Information

1. 国家儿童医学中心，首都医科大学附属北京儿童医院，北京市儿科研究所，中国医学科学院儿童危重感染诊治创新单元，国家呼吸系统疾病临床医学研究中心，儿科重大疾病研究教育部重点实验室，儿童呼吸道感染性疾病研究北京市重点实验室，北京　100045
Keywords: Respiratory syncytial virus; Infant; Long-acting monoclonal antibody; Nirsevimab
From: Chinese Journal of Applied Clinical Pediatrics 2022;37(7):481-485
CountryChina
Language:Chinese
Abstract: Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infection (LRTI) and hospitalizations in infants under 1 year of age, seriously jeopardizing infants′ health.Most hospitalizations (up to 80%) due to RSV-LRTI occur in otherwise healthy infants born at term.At present, no effective treatment and preventative measure against RSV is available domestically.Passive immunization with fully human long-acting monoclonal antibody Nirsevimab offers immediate protection for all infants experiencing their first RSV season with one shot, thus ushering in a new era of prevention of RSV infection among infants.